Recent searches
Search options
Administered by:
https://open.substack.com/pub/insidemedicine/p/breaking-news-semaglutide-ozempic?r=roppe&utm_medium=ios&utm_campaign=post “Brand new high-quality data indicate that #semaglutide (the generic name for the blockbuster diabetes and obesity medication #Ozempic) is effective in improving symptoms of a certain hard-to-treat type of #HeartFailure. The just-released study—a double-blinded placebo-controlled randomized clinical trial of obese adults—appears in the New England Journal of Medicine.”
“In patients with #HeartFailure with preserved ejection fraction #HFpEF and #obesity, treatment with #semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo.”